Clinical Trials Logo

Recurrent Pericarditis clinical trials

View clinical trials related to Recurrent Pericarditis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05494788 Active, not recruiting - Clinical trials for Recurrent Pericarditis

Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)

Start date: November 30, 2022
Phase: Phase 2
Study type: Interventional

Patients with recurrent pericarditis who are refractory or intolerant to current therapeutic management options or who require long-term administration of corticosteroids to control their disease are particularly challenging to manage. The pathogenesis of pericarditis involves the activation of the inflammasome. CardiolRxTM (a pure cannabidiol [CBD] solution) is known to have anti-inflammatory properties, including modulation of inflammasome signaling. This pilot study is to assess the tolerance and safety of CardiolRxTM during the resolution of pericarditis symptoms, assess improvement in objective measures of disease, and during the extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids while taking CardiolRxTM.